Assessment of transfer entropy is useful for network analysis of cell signaling network providing information on the network topology and action points of genetic mutations and drug effect, thus will ...

Cardiff Oncology's Onvansertib shows promise in treating RAS-mutated cancers, especially mCRC. See why I rate CRDF stock as a strong buy.

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...

Project Optimus seeks to transform how doses are selected and optimised in oncology drug development. As this initiative ...

Operator: Welcome to the Cardiff Oncology Fourth Quarter 2024 Financial Results and Business Update Conference Call.

KOMET-001 registrational trial in R/R NPM1-mutant AML achieved primary endpoint –– Alignment reached with FDA and EMA on key aspects of the ...

Mark Erlander; Chief Executive Officer, Director; Cardiff Oncology Inc. James Levine; Chief Financial Officer; Cardi ...

They result from germline mutations in genes encoding kinases and other proteins interacting in the RAS-MAPK pathway. This review summarises these disorders, discussing their presenting features and ...

Colorectal cancer and pancreatic ductal adenocarcinoma that harbored the KRAS G12C mutation often carried other genetic alterations that can be associated with resistance to KRAS G12C inhibitors, ...